Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Anticoagulant drugs in the elderly: valuable in selected patients.

Literature DB >> 3145075

Anticoagulant drugs in the elderly: valuable in selected patients.

G D Lowe¹.

Abstract

Entities: Species

Mesh：

Substances：
Anticoagulants

Year: 1988 PMID： 3145075 PMCID： PMC1834733 DOI： 10.1136/bmj.297.6658.1260

Source DB: PubMed Journal: BMJ ISSN： 0959-8138

× No keyword cloud information.

13 in total

1. Prevention of venous thrombosis and pulmonary embolism in injured patients. A trial of anticoagulant prophylaxis with phenindione in middle-aged and elderly patients with fractured necks of femur.

Authors: S SEVITT; N G GALLAGHER
Journal: Lancet Date: 1959-12-05 Impact factor: 79.321

2. Determinants of anticoagulant control in patients receiving warfarin.

Authors: K O'Malley; I H Stevenson; C A Ward; A J Wood; J Crooks
Journal: Br J Clin Pharmacol Date: 1977-06 Impact factor: 4.335

3. Cooperative study on the value of long term anticoagulation in patients with stroke and non-rheumatic atrial fibrillation.

Authors: J Lodder; M S Dennis; L Van Raak; L N Jones; C P Warlow
Journal: Br Med J (Clin Res Ed) Date: 1988-05-21

Review 4. Reduction in fatal pulmonary embolism and venous thrombosis by perioperative administration of subcutaneous heparin. Overview of results of randomized trials in general, orthopedic, and urologic surgery.

Authors: R Collins; A Scrimgeour; S Yusuf; R Peto
Journal: N Engl J Med Date: 1988-05-05 Impact factor: 91.245

5. Reduction of mortality in general medical in-patients by low-dose heparin prophylaxis.

Authors: H Halkin; J Goldberg; M Modan; B Modan
Journal: Ann Intern Med Date: 1982-05 Impact factor: 25.391

6. A randomized controlled trial of a low-molecular-weight heparin (enoxaparin) to prevent deep-vein thrombosis in patients undergoing elective hip surgery.

Authors: A G Turpie; M N Levine; J Hirsh; C J Carter; R M Jay; P J Powers; M Andrew; R D Hull; M Gent
Journal: N Engl J Med Date: 1986-10-09 Impact factor: 91.245

7. Prognostic value of beta-thromboglobulin in patients with transient cerebral ischaemia.

Authors: M E Stewart; J T Douglas; G D Lowe; C R Prentice; C D Forbes
Journal: Lancet Date: 1983-08-27 Impact factor: 79.321

8. Predictors of bleeding during heparin therapy.

Authors: A M Walker; H Jick
Journal: JAMA Date: 1980-09-12 Impact factor: 56.272

9. Low-dose subcutaneous heparin in the prevention of deep-vein thrombosis and pulmonary emboli following acute stroke.

Authors: S T McCarthy; J Turner
Journal: Age Ageing Date: 1986-03 Impact factor: 10.668

10. Double-blind randomised trial of Org 10172 low-molecular-weight heparinoid in prevention of deep-vein thrombosis in thrombotic stroke.

Authors: A G Turpie; M N Levine; J Hirsh; C J Carter; R M Jay; P J Powers; M Andrew; H N Magnani; R D Hull; M Gent
Journal: Lancet Date: 1987-03-07 Impact factor: 79.321

8 in total

Anticoagulant drugs in the elderly: valuable in selected patients.

1. Prevention of venous thrombosis and pulmonary embolism in injured patients. A trial of anticoagulant prophylaxis with phenindione in middle-aged and elderly patients with fractured necks of femur.

2. Determinants of anticoagulant control in patients receiving warfarin.

3. Cooperative study on the value of long term anticoagulation in patients with stroke and non-rheumatic atrial fibrillation.

Review 4. Reduction in fatal pulmonary embolism and venous thrombosis by perioperative administration of subcutaneous heparin. Overview of results of randomized trials in general, orthopedic, and urologic surgery.

5. Reduction of mortality in general medical in-patients by low-dose heparin prophylaxis.

6. A randomized controlled trial of a low-molecular-weight heparin (enoxaparin) to prevent deep-vein thrombosis in patients undergoing elective hip surgery.

7. Prognostic value of beta-thromboglobulin in patients with transient cerebral ischaemia.

8. Predictors of bleeding during heparin therapy.

9. Low-dose subcutaneous heparin in the prevention of deep-vein thrombosis and pulmonary emboli following acute stroke.

10. Double-blind randomised trial of Org 10172 low-molecular-weight heparinoid in prevention of deep-vein thrombosis in thrombotic stroke.

1. Safety of anticoagulation in the elderly: reasons for discontinuing therapy.

2. Anticoagulant treatment as a risk factor for primary intracerebral haemorrhage.

Review 3. Adverse reactions as a cause of hospital admission in the aged.

Review 4. Anticoagulants in older patients. A safety perspective.

5. Anticoagulant drugs in the elderly.

6. Anticoagulant drugs in the elderly.

7. A hospital study of community acquired pneumonia in the elderly.

Review 8. Adverse drug reactions. An overview of special considerations in the management of the elderly patient.